Welcome to our dedicated page for Immunome news (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome stock.
Immunome, Inc. develops targeted cancer therapies through a clinical-stage oncology pipeline that includes varegacestat, an investigational oral gamma secretase inhibitor for desmoid tumors, IM-1021, a ROR1 antibody-drug conjugate, and IM-3050, a FAP-targeted radiotherapy. Company news commonly covers clinical data, regulatory submissions, IND-related progress, oncology conference presentations, and updates on antibody-drug conjugate programs for solid tumors.
Recurring corporate updates also include financial results, business progress reports, investor conference participation, equity compensation actions under the 2024 Inducement Plan, and Nasdaq Listing Rule 5635(c)(4) inducement grants for new employees.
Immunome (Nasdaq: IMNM) presented preclinical data on Oct. 23, 2025 showing its proprietary ADC payload HC74 overcomes several ADC resistance mechanisms, including payload efflux and target heterogeneity.
The poster reported HC74 is a novel topoisomerase I inhibitor used in IM-1021 (a ROR1-targeted ADC in Phase 1) and in multiple preclinical candidates; key findings include high membrane permeability, robust bystander activity, and efficacy in preclinical models refractory or resistant to trastuzumab-DXd, irinotecan, and models with heterogeneous target expression.
A copy of the poster is available in the company’s Events & Presentations materials.
Immunome (Nasdaq: IMNM) announced that on Oct. 1, 2025 its Compensation Committee granted inducement awards of 69,000 non‑statutory stock options to purchase common stock to five new employees under the 2024 Inducement Plan.
Each option has an exercise price of $11.34 equal to the Company’s closing price on Oct. 1, 2025, and vests over four years (25% at one year, then monthly over 36 months), subject to continued service and the terms of the 2024 Inducement Plan and the applicable stock option agreements. The grants were approved as inducements under Nasdaq Listing Rule 5635(c)(4).
Immunome (NASDAQ:IMNM) has entered into a research collaboration agreement with Infinimmune for novel antibody discovery and optimization. The partnership leverages Infinimmune's GLIMPSE™ and Anthrobody® platforms to transform early-stage antibodies into development-ready therapeutic candidates.
Under the agreement, Immunome receives target exclusivity, with Infinimmune handling antibody discovery and optimization while Immunome will manage development and commercialization of resulting candidates. Financial terms were not disclosed.
Immunome (Nasdaq: IMNM), a biotechnology company specializing in targeted cancer therapies, has announced inducement grants to new employees. The Compensation Committee approved non-statutory stock options for 117,000 shares of common stock to 8 new employees under the company's 2024 Inducement Plan.
The stock options have an exercise price of $9.28 per share, based on the company's closing price on September 2, 2025. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months, contingent on continued employment.
Immunome (NASDAQ:IMNM), a biotechnology company specializing in targeted cancer therapies, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. The company's management will deliver a presentation on Tuesday, September 9, 2025, at 1:00 p.m. Eastern Time.
Investors and interested parties can access the presentation through a live audio webcast available on the Investor Relations section of Immunome's website. The presentation recording will remain accessible for approximately 30 days following the live event.
Immunome (Nasdaq: IMNM), a biotechnology company developing targeted cancer therapies, reported its Q2 2025 financial results and pipeline updates. The company's cash position of $268.0 million is expected to fund operations into 2027.
Key pipeline developments include: varegacestat's upcoming Phase 3 RINGSIDE topline data expected by end of 2025 and recent European Medicines Agency Orphan Drug Designation; IM-1021's ongoing Phase 1 trial reaching its third dose level; and IM-3050's IND clearance with Phase 1 trial initiation planned for late 2025. Three additional preclinical ADCs (IM-1617, IM-1340, and IM-1335) are undergoing IND-enabling work.
Q2 2025 financials showed R&D expenses of $40.5 million and G&A expenses of $10.0 million, with a net loss of $43.4 million.
Immunome (Nasdaq: IMNM), a biotechnology company developing targeted cancer therapies, has granted inducement stock options to 5 new employees under its 2024 Inducement Plan. The Compensation Committee approved options to purchase 39,000 shares of common stock at an exercise price of $10.59 per share.
The stock options will vest over a four-year period, with 25% vesting after one year and the remaining balance vesting monthly over the following 36 months, contingent on continued employment.
Immunome (Nasdaq: IMNM), a biotechnology company specializing in targeted cancer therapies, announced inducement grants to 8 new employees under its 2024 Inducement Plan. The Compensation Committee approved non-statutory stock options to purchase 125,500 shares of common stock at an exercise price of $8.47 per share.
The stock options will vest over a four-year period, with 25% vesting after one year and the remaining balance vesting monthly over the following 36 months, contingent on continued employment.
Immunome (NASDAQ: IMNM), a biotechnology company specializing in targeted cancer therapies, has announced its participation in two upcoming investor conferences. The company will present at the TD Cowen 6th Annual Oncology Innovation Summit on May 27, 2025, from 6:30 AM to 7:00 AM PT, and at the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, from 11:00 AM to 11:35 AM PT. Live webcasts and 30-day replay links for both presentations will be accessible through the events section of Immunome's investor website.